Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beilu Pharmaceutical Raises Funds For CT Contrast Agents

This article was originally published in PharmAsia News

Executive Summary

Beijing Beilu Pharmaceutical has completed issuing 12.5 million additional shares to seven investors and raised RMB 66.625 million. The funds will be invested in the firm's CT contrast agents iopamidol and iodixanol injections to strengthen both products' leading position domestically as well as compete with MNCs. Currently, China's iopamidol market is exclusively monopolized by Italian firm Bracco's local joint venture product Isovue, but Beilu believes that there is still room for growth. GE's imported Visipaque represents the only iodixanol available in the country but its patent protection will expire in June 2010. Beilu aims to develop the iodixanol sector to expand its economic and social benefits in China. (Click here for more - Chinese Language)

You may also be interested in...



Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel